ArticleTurkish journal of medical sciences2025
Irisin and adropin decrease in preobese or obese individuals with nonalcoholic fatty liver disease.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease that is commonly observed in individuals with obesity. The present study investigates the irisin and adropin levels of sera in preobese or obese adults with NAFLD. Materials and methods: Included in the study were 89 patients who were categorized into four groups: Group 1: 25 normal-weight individuals without NAFLD (Control group); Group 2: 17 preobese or obese individuals without NAFLD; Group 3: 24 preobese or obese individuals with Grade 1 NAFLD; and Group 4: 23 preobese or obese individuals with Grade 2-3 NAFLD. The demographic details of all participants were recorded. Abdominal ultrasonography and anthropometric assessments were conducted. Serum adropin and irisin levels were determined using the Enzyme-Linked Immunosorbent Assay (ELISA) method. Results: Serum adropin and irisin levels were lower in Groups 3 and 4 than in Group 1 (between the all groups; p = 0.006, p = 0.001, respectively), but were comparable between Groups 3 and 4. Furthermore, the atherogenic index of Group 1 was lower than that of Group 4 (p < 0.001). Among the hemogram parameters, the red cell distribution width value was higher in Group 3 than in Group 1 (p = 0.031). Conclusion: Serum adropin and irisin levels decrease in the presence of NAFLD, regardless of disease severity, which may play a role in the development and exacerbation of NAFLD in preobese and obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.